Announcement on Convening the Q1 2026 Performance Briefing
Filed with SSE · · 2 pages · Chinese
Jiangsu Hengrui Pharmaceuticals Co., Ltd. on 6ix
Earlier from Jiangsu Hengrui Pharmaceuticals
- Announcement on Implementation of Dividend Distribution for 2025
- Hengrui Pharma and Bristol Myers Squibb Announce Strategic Agreements to Advance Innovative Medicines Across Oncology, Hematology, and Immunology
- Hengrui Pharma and Braveheart Bio Announce Positive Phase 2 Results with HRS/BHB-1893 in Non-Obstructive Hypertrophic Cardiomyopathy
- Announcement on Resolutions of the 3rd Meeting of the 10th Board of Directors
- Hengrui Pharma Reports Q1 2026 Results with Revenue and Net Profit Growth
Later from Jiangsu Hengrui Pharmaceuticals
- Announcement on Progress in A-share Repurchase
- Announcement on Obtaining Notice of Approval for Drug Clinical Trial
- Indicative Announcement on Acceptance of Application for Drug Marketing Authorization by EMA
- Announcement on Withdrawal of Drug Registration Application
- Announcement on Obtaining Drug Registration Approval
Follow Jiangsu Hengrui Pharmaceuticals into a list and get an email when it puts out news.
Follow Jiangsu Hengrui Pharmaceuticals